Elamipretide

Drug Profile

Elamipretide

Alternative Names: Bendavia; ELA 4; MTP 131; Ocuvia; SBT-31; SPI-31; SS-31

Latest Information Update: 19 May 2017

Price : $50

At a glance

  • Originator Stealth Peptides
  • Developer Stealth BioTherapeutics
  • Class Eye disorder therapies; Ischaemic heart disorder therapies; Oligopeptides; Peptides; Small molecules
  • Mechanism of Action Mitochondrial permeability transition pore inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Barth syndrome
  • Phase II Acute kidney injury; Corneal disorders; Heart failure; Leber's hereditary optic atrophy; Mitochondrial disorders; Reperfusion injury
  • Phase I/II Diabetic macular oedema; Dry age-related macular degeneration; Mitochondrial myopathies
  • Phase I Age-related macular degeneration
  • No development reported Chronic heart failure; Diabetes mellitus; Eye disorders; Neurodegenerative disorders

Most Recent Events

  • 01 May 2017 Phase-II/III clinical trials in Barth syndrome (In children, In adolescents, In adults, In the elderly) in USA (SC) (NCT03098797)
  • 06 Apr 2017 Stealth BioTherapeutics plans the TAZPOWER phase II/III trial for Barth Syndrome in USA (NCT03098797)
  • 01 Dec 2016 Stealth BioTherapeutics initiates an extension phase II trial for Mitochondrial disorders (In adolescents, In adults) in USA (SC) (NCT02976038)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top